138 related articles for article (PubMed ID: 35948326)
1. Serum Ceruloplasmin as a Potential Clinical Biomarker in Atopic Dermatitis.
Bae Y; Kim SJ
Ann Dermatol; 2022 Aug; 34(4):245-252. PubMed ID: 35948326
[TBL] [Abstract][Full Text] [Related]
2. Gelsolin as a Potential Clinical Biomarker in Psoriasis Vulgaris.
Lee SH; Park YL; Bae Y
J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902587
[TBL] [Abstract][Full Text] [Related]
3. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.
Chopra R; Vakharia PP; Sacotte R; Patel N; Immaneni S; White T; Kantor R; Hsu DY; Silverberg JI
Br J Dermatol; 2017 Nov; 177(5):1316-1321. PubMed ID: 28485036
[TBL] [Abstract][Full Text] [Related]
4. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.
Schmitt J; Langan S; Deckert S; Svensson A; von Kobyletzki L; Thomas K; Spuls P;
J Allergy Clin Immunol; 2013 Dec; 132(6):1337-47. PubMed ID: 24035157
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
[TBL] [Abstract][Full Text] [Related]
7. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
8. Correlation between serum vitamin d level and the severity of atopic dermatitis associated with food sensitization.
Lee SA; Hong S; Kim HJ; Lee SH; Yum HY
Allergy Asthma Immunol Res; 2013 Jul; 5(4):207-10. PubMed ID: 23814673
[TBL] [Abstract][Full Text] [Related]
9. Two-dimensional electrophoresis analyses of atopic dermatitis and the chances to detect new candidate proteins by the variations in immobilized pH gradient strips.
Park YD; Lyou YJ; Yang JM
J Dermatol Sci; 2007 Jul; 47(1):9-17. PubMed ID: 17353112
[TBL] [Abstract][Full Text] [Related]
10. The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity.
van Velsen SG; Knol MJ; Haeck IM; Bruijnzeel-Koomen CA; Pasmans SG
Pediatr Dermatol; 2010; 27(5):470-5. PubMed ID: 20796235
[TBL] [Abstract][Full Text] [Related]
11. Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer's disease.
Dey KK; Wang H; Niu M; Bai B; Wang X; Li Y; Cho JH; Tan H; Mishra A; High AA; Chen PC; Wu Z; Beach TG; Peng J
Clin Proteomics; 2019; 16():16. PubMed ID: 31019427
[TBL] [Abstract][Full Text] [Related]
12. Proteomic signatures of inflammatory skin diseases: a focus on atopic dermatitis.
Mikhaylov D; Del Duca E; Guttman-Yassky E
Expert Rev Proteomics; 2021 May; 18(5):345-361. PubMed ID: 34033497
[No Abstract] [Full Text] [Related]
13. Comparative Proteomic Analysis Reveals Novel Biomarkers for Gastric Cancer in South Indian Tamil Population.
Sivagnanam A; Thangasamy B; Nagarajan V; Ravi SG; Madhesh JC; Perumal MA; Karunakaran P; Jayaraman M
Comb Chem High Throughput Screen; 2022; 25(8):1361-1373. PubMed ID: 34082671
[TBL] [Abstract][Full Text] [Related]
14. The Atopic Dermatitis Antecubital Severity score: validity, reliability, and sensitivity to change in patients with atopic dermatitis.
Baek JH; Park CW; Choi KM; Yang YS; Lee SY; Koh JS; Chung BY; Kim HO; Park GH
Int J Dermatol; 2015 Dec; 54(12):1382-9. PubMed ID: 25556325
[TBL] [Abstract][Full Text] [Related]
15. What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.
Silverberg JI; Lei D; Yousaf M; Janmohamed SR; Vakharia PP; Chopra R; Chavda R; Gabriel S; Patel KR; Singam V; Kantor R; Hsu DY
Br J Dermatol; 2021 May; 184(5):888-895. PubMed ID: 32959390
[TBL] [Abstract][Full Text] [Related]
16. Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies.
Kim HS; Lee JH; Roh KH; Jun HJ; Kang KS; Kim TY
Stem Cells; 2017 Jan; 35(1):248-255. PubMed ID: 27256706
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin free light chains in adult atopic dermatitis patients do not correlate with disease severity.
Thijs JL; Knipping K; Bruijnzeel-Koomen CA; Garssen J; de Bruin-Weller MS; Hijnen DJ
Clin Transl Allergy; 2016; 6():44. PubMed ID: 27980722
[TBL] [Abstract][Full Text] [Related]
18. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review.
Iannone M; Tonini G; Janowska A; Dini V; Romanelli M
Curr Med Res Opin; 2021 Aug; 37(8):1295-1301. PubMed ID: 34027753
[TBL] [Abstract][Full Text] [Related]
19. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
[TBL] [Abstract][Full Text] [Related]
20. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
